We hope that our study will pave the way for future international studies conducted in a well-planned manner, for instance, by comparing two drugs inhibiting the PIK3CA/mTOR pathway, e.g., sirolimus and alpelisib, to further delineate the value of these drugs in the treatment of extensive LM of the head and neck region. The gene discussed is MTOR; the disease is lymphangioma.